Form 4 for SPRY ARS Pharmaceuticals, Inc.
Accepted 2024-08-21 00:00:00 ET · period of report 2024-08-19 · accession 0001415889-24-021885 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-08-21 | 2024-08-19 | SPRY | Karas Eric | Chief Commercial Off | M - OptEx | $1.50 | +10.0K | 15.7K | +176% | +$15.0K |
| D | 2024-08-21 | 2024-08-19 | SPRY | Karas Eric | Chief Commercial Off | S - Sale+OE | $14.00 | -10.0K | 5,693 | -64% | -$140.0K |
| D | 2024-08-21 | 2024-08-19 | SPRY | Karas Eric | Chief Commercial Off | M - OptEx | $0.00 | -10.0K | 604.6K | -2% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-08-19 | M | A | 10,000 | $1.50 | 15,693 | D | — | — | (F1) Includes 1,984 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan ("ESPP") on June 30, 2023, 1,232 shares acquired under the ESPP on December 29, 2023 and 2,477 shares acquired under the ESPP on June 28, 2024. |
| 2 | Common | Common Stock | 2024-08-19 | S | D | 10,000 | $14.00 | 5,693 | D | — | — | |
| 3 | Derivative | Stock Option (Right to Buy) | 2024-08-19 | M | D | 10,000 | $0.00 | 604,588 | D | $1.50 · — to 2032-05-23 | 10,000 Common Stock | (F3) Immediately exercisable. |